الفهرس 
ContentsOnly 14 pages are availabe for public view
 |  | from | 77 |  |  |
| | | from | 77 | | |
Abstract
SUMMARY AND CONCLUSION
AJlopurino] is used commonly 10 prevent recurrent calcium oxalate stone formation, not only in patients with hyperuricosuria but also in patients with normal uraie excretion. Encouraging stone prophylactic effects have been reported in both categories of patients. Thus the present study have investigated the effect of allopunnol on oxaluda in patients with oxatate stones.
Twenty patients have been divided into two groups according to serum uric acid level, those beJow5.fJ44 mg/dl (300 umot/L) ;,nd above it.
There was significant reduction in serum and urinary uric iicid. The mean urinary oxalate tevet in group I was 15.3^5.6 mg/gm creatinine and lOjji.9 before and after treatment respectively and in group II, it was I3.6_+_7,2 and 12.3^+4,5 mg/gm creannine before and after treatment respectively. These resuU.s were ^[arisiicaJly not significant. Thus we conclude [hat allopurinol hai no effect on urinary excretion of oxalate and its beneficial effect in prophylactic properties against stone recurrences could be due to other factors rather than decreased urinary ox a late excretion.